What Is Awiqli, and Why Does It Matter? Awiqli (insulin icodec-abae) is a once-weekly long-acting basal insulin injection approved by the FDA for adults with type 2 diabetes. It helps lower blood ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S’ NVO Awiqli (insulin icodec-abae), marking the first once-weekly basal insulin for adults with Type 2 diabetes. The ...
Data from the ONWARDS clinical trial program supported the efficacy of once-weekly insulin icodec-abae compared with daily basal insulin. The Food and Drug Administration (FDA) has approved Awiqli ® ...
Awiqli (insulin icodec) is a long-acting insulin used along with diet and exercise to help manage blood sugar in people with type 2 diabetes. It is injected under the skin once a week. Like all ...
Kresladi becomes the first FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2, and Awiqli the first and only once-weekly basal insulin treatment for adults ...
The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 -- ...
PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results